Education
About Us
Working with TipRanks
Follow Us
Palisade Bio, Inc. (PALI)
:PALI
PALI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $9.65
Previous CloseN/A
Volume307.14K
Average Volume (3M)502.97K
Market Cap
$3.03M
Enterprise Value-$7.67M
Total Cash (Recent Filing)$5.79M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.90
Next Earnings
May 09, 2025EPS Estimate
-1.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.03
Shares Outstanding4,396,646
10 Day Avg. Volume142,700
30 Day Avg. Volume502,966
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.78
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-2.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.69
Enterprise Value/Ebitda0.53
Forecast
1Y Price Target
$2.00Price Target Upside189.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementAnalysts reiterate a buy recommendation based on the market opportunity in ulcerative colitis and the advancement of the PALI-2108 phase 1 trial.
Market OpportunityThe global inflammatory bowel disease market is estimated at over $20 billion, presenting a significant market opportunity for PALI-2108 if successful.
Safety DataPositive preliminary safety data seen in Phase 1a/b study and first ulcerative colitis (UC) patient enrolled.
Bears Say
Financial PerformancePalisade reported 3Q24 results with a net loss of ($3.5M) and ended the period with $8.0M in cash, which should provide sufficient funding into 2Q25.
Financing NeedsThe analyst's recommendation includes a lower 12-month price target due to expected dilution from future financing needs.
Stock PerformancePALI shares have traded down since the spring and the company will have to conduct another financing in the near-term, which can occur in various forms.
---
Ownership Overview
0.79% Insiders
0.53% Mutual Funds
3.81% Other Institutional Investors
94.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PALI FAQ
What was Palisade Bio, Inc.’s price range in the past 12 months?
Palisade Bio, Inc. lowest stock price was $0.65 and its highest was $9.65 in the past 12 months.
What is Palisade Bio, Inc.’s market cap?
Palisade Bio, Inc.’s market cap is $3.03M.
When is Palisade Bio, Inc.’s upcoming earnings report date?
Palisade Bio, Inc.’s upcoming earnings report date is May 09, 2025 which is in 38 days.
How were Palisade Bio, Inc.’s earnings last quarter?
Palisade Bio, Inc. released its earnings results on Mar 14, 2025. The company reported -$2.79 earnings per share for the quarter, missing the consensus estimate of -$1.58 by -$1.21.
Is Palisade Bio, Inc. overvalued?
According to Wall Street analysts Palisade Bio, Inc.’s price is currently Undervalued.
Does Palisade Bio, Inc. pay dividends?
Palisade Bio, Inc. does not currently pay dividends.
What is Palisade Bio, Inc.’s EPS estimate?
Palisade Bio, Inc.’s EPS estimate is -1.99.
How many shares outstanding does Palisade Bio, Inc. have?
Palisade Bio, Inc. has 4,396,646 shares outstanding.
What happened to Palisade Bio, Inc.’s price movement after its last earnings report?
Palisade Bio, Inc. reported an EPS of -$2.79 in its last earnings report, missing expectations of -$1.58. Following the earnings report the stock price went up 8.696%.
Which hedge fund is a major shareholder of Palisade Bio, Inc.?
Currently, no hedge funds are holding shares in PALI
---
Company Description
Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
---
PALI Stock 12 Month Forecast
Average Price Target
$2.00
▲(189.86% Upside)
Technical Analysis
Ardelyx
―
Ascendis Pharma
―
Voyager Therapeutics
―
Bioxcel Therapeutics
―
Mirum Pharmaceuticals
―
Best Analysts Covering PALI
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-75.21%
reiterated a buy rating 6 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -75.21% per trade.
---